Black Diamond Therapeutics Newsroom

Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances

TipRanksSep 18 06:25 ET · Ratings

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients With Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswireSep 14 03:30 ET

Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsSep 10 08:33 ET · Ratings

Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsSep 10 08:33 ET · Ratings

Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsSep 10 07:31 ET · Ratings

Black Diamond Therapeutics (BDTX) Gets a Buy From Piper Sandler

TipRanksSep 10 06:36 ET · Ratings

H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11

Moomoo NewsSep 4 06:31 ET · Ratings

Looking Into Black Diamond Therapeutic's Recent Short Interest

BenzingaAug 22 09:15 ET

Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM

Seeking AlphaAug 19 15:07 ET

Catalyst Watch: Eyes on Walmart Earnings, the July CPI Print, and 13F Filings

Seeking AlphaAug 9 15:00 ET

Institutional Owners May Ignore Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Recent US$67m Market Cap Decline as Longer-term Profits Stay in the Green

Simply Wall StAug 9 09:20 ET

Express News | Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.d., to Board of Directors

ReutersAug 8 16:05 ET

Wedbush Reiterates Outperform on Black Diamond Therapeutic, Maintains $16 Price Target

BenzingaAug 7 10:37 ET · Ratings

Black Diamond Therapeutic Analyst Ratings

BenzingaAug 7 10:35 ET · Ratings

TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating

Moomoo NewsAug 6 17:32 ET · Ratings

Buy Rating on Black Diamond Therapeutics: Promising Early Results for BDTX-1535 in NSCLC Treatment

TipRanksAug 6 16:46 ET · Ratings

Express News | Black Diamond Therapeutics' Cash, Cash Equivalents, And Investments Of $123M As Of June 30, 2024, Expected To Be Sufficient To Fund Operations Into Q4 Of 2025

BenzingaAug 6 07:45 ET

Express News | Black Diamond Therapeutic Q2 2024 GAAP EPS $(0.36) Misses $(0.35) Estimate

BenzingaAug 6 07:44 ET

Earnings Flash (BDTX) BLACK DIAMOND THERAPEUTICS Posts Q2 Loss $-0.36 Per Share

MT NewswiresAug 6 07:31 ET

Express News | Black Diamond Therapeutics Inc: On Track to Announce Initial Phase 2 Data of Bdtx-1535 in 1L Patients With Non-Classical Egfrm Nsclc in Q1 2025

ReutersAug 6 07:30 ET